This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Proactive: Race Oncology submits human ethics for RC220 Phase 1 solid tumour trial
Race Oncology Ltd (ASX:RAC, OTC:RAONF) has taken another key step toward a Phase 1 trial in solid tumour patients using RC220 bisantrene by submitting an application for an ethics and regulatory package to Bellberry Human Research Ethics Committee (HREC) for approval.
Read the full article here.
Watch the interview with CEO and MD Dr Daniel Tillett.